After successful trials in monkey, researchers plan to inject 5 million iPS cells into patient brains.

Japanese researchers on Monday announced the first human trial using a kind of stem cell to treat Parkinson’s disease, building on earlier animal trials.

The research team at Kyoto University plans to inject five million induced Pluripotent Stem (iPS) cells, which have the potential to develop into any cell in the body, into patient brains, the university said in a press release.

The iPS cells from healthy donors will be developed into dopamine-producing brain cells, which are no longer present in people with Parkinson’s disease.

Parkinson’s disease is a chronic, degenerative neurological disorder that affects the body’s motor system, often causing shaking and other difficulties in movement.

Worldwide, about 10 million people have the illness, according to the Parkinson’s Disease Foundation.

The clinical trials come after the researchers successfully used iPS cells to restore functioning brain cells in monkeys last year. They announced last year that primates with Parkinson’s symptoms regained significant mobility after iPS cells were inserted into their brains.

iPS cells are created by stimulating mature, already specialised, cells back into a juvenile state — basically cloning without the need for an embryo. These can be derived from the patient, making them less likely to be rejected, while also sidestepping ethical qualms about taking cells from embryos.

The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.

Currently available therapies “improve symptoms without slowing or halting the disease progression,” the foundation says.

But the new research aims to actively reverse the disease.

Monitoring period

The clinical test with seven participants aged between 50 and 69 will begin on Wednesday.

The university will monitor the conditions of the patients for two years after the operation.

They also confirmed that the iPS cells had not transformed into tumors during the two years after the implant.

iPS cells are created by stimulating mature, already specialised, cells back into a juvenile state — basically cloning without the need for an embryo.

These can be derived from the patient, making them less likely to be rejected, while also sidestepping ethical qualms about taking cells from embryos. The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.

In 2014, Riken, a Japanese government-backed research institution, carried out the world’s first surgery to implant iPS cells to treat a patient with age-related macular degeneration (AMD), a common medical condition that can lead to blindness in older people.

 

 

Source : thehindu

Useful Links

Newsletter Subscription

captcha

Advancells

A-102, Sector-V Noida-201301, UP, India

Tel: +91-9654321400

Email: info@advancells.com 

 

 

Partner With Us

Newsletter Subscription

captcha

"Advancells is a strong advocate of greater transparency in medical procedures in general and Stem Cells Procedures in particular. As a part of our effort of bringing transparent procedures to our clients, we provide each client a Third Party Certificate (from an internationally accredited lab) for the cell count and viability of the cells that we are able to process from the autologous cell source of the patient. To view the sample copy of the certificate  "click here"

By Advancells. Copyright 2018. All Rights Reserved. All images and content used in this site are original. Any attempt to copy will come under criminal jurisdiction.